Conclusions
heart disease
HEART DISEASE
In the Beta3-LVH randomized clinical trial, the standard therapeutic mirabegron dosage (50 mg/d) did not result in a difference in LV mass or diastolic function over 12-month follow-up in patients who had structural heart disease but no or mild HF symptoms and were receiving standard therapy. Unlike smaller trials using higher dosages for patients with severe illness,